Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor [...]
Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor [...]
Dale Levitzke, CEO of Sphere Fluidics, expressed his pride in [...]
Tianlong’s Biolum Portable ATP Hygiene Monitoring System, a powerful tool [...]
The grant was awarded through MJFF’s Parkinson’s Disease Therapeutics Pipeline [...]
Dr Kambiz Shekdar said: “I gratefully take this opportunity as [...]
“We celebrate the growing base of research and technological advances [...]
Through the HOPE Program, patients across the globe can receive [...]
The trial, which aimed to replicate and expand an earlier [...]
The new Roden ADA Kit expedites bioanalysis by removing the [...]
Since the inception of their partnership five years ago, ATLATL [...]